Abstract: Disclosed are methods for the removal of plaques containing amyloid beta, protecting the brain from amyloid beta toxicity, and restoring neurological function by the expansion of neural stem cell pools and improving mitochondrial health.

Abstract: Disclosed herein are personal care and/or cosmetic compositions, comprising a carrier and oolitic aragonite beads having an average diameter between 10 nm to 10 mm. Also disclosed herein are methods of reducing plastic contamination and/or pollution comprising making a cosmetic or personal care composition, wherein at least a portion to all (100%) of the plastic microbeads in the cosmetic or personal care composition are replaced with oolitic aragonite. Also disclosed herein are a milling system and milling methods for producing oolitic aragonite particles having a clean top size in which the particles are screened to remove any oversized particles. Additional uses include drug-loaded aragonite particles for therapeutic drug delivery and chromatography media.

Abstract: Disclosed are methods and compositions of reducing the epigenetic age of mammalian organism, especially an adult human of geriatric age. The methods provide for the proliferation of endogenous stem cells using mitochondrial fusion and a UCP2 blocker or other stimulants; supplying stem cells with nutrition to prevent cell cycle arrest; and removal of senescent somatic cells using senolytic treatments. The proliferation of endogenous neural stem cells after plaque removal for the treatment of Alzheimer's is also disclosed.

Abstract: The present invention concerns a highly selective process for the preparation of an ingredient comprising 1,3-Olein-2-palmitin (OPO), a triglyceride present in human breast milk. The present invention also relates to 1,3-Olein-2-palmitin (OPO) ingredient obtainable by the process.

Abstract: The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.

Abstract: The invention relates to the treatment and reduction of fibrosis, specifically hepatic fibrosis. More specifically, embodiments of the invention provide compositions and methods useful for the treatment and inhibition of hepato-fibrotic conditions associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), employing the use of 3?-arachidylamido-7?,12?-dihydroxy-5?-cholan-24-oic acid (Aramchol) or a pharmaceutically acceptable salt thereof. In other embodiments, the treatment and inhibition of hepato-fibrotic conditions caused by contact with hepatotoxic chemical substances or by mechanical obstruction is contemplated.

Abstract: A method of reducing the virulence of microbes in or on the human body and a method of sanitizing or disinfecting a surface, area, object, or porous or non porous material is provided. The methods comprise applying or injecting a solution having an effective amount of a conjugated diene for substantially reducing the virulence of the microbes or sanitizing or disinfecting a surface, area, object, or porous or non porous material.

Abstract: Methods of treating anxiety disorders or reducing anxiety-related behaviors. The methods include administering a therapeutically effective amount of ketone supplementation, such as butanediol, ketone esters (e.g., 1,3-butanediol-acetoacetate diester) and/or ketone salts (e.g., beta-hydroxybutyrate-mineral salt), chronically, sub-chronically, or acutely, with or without admixture with a medium chain triglyceride or in combination. It was determined herein that ketone supplementation reduced anxiety in rats on elevated plus maze as measured by less entries to closed arms, more time spent in open arms, more distance travelled in open arms, and delayed latency to entrance to closed arms, when compared to control. Along with reducing anxiety-related behavior, the chronic, sub-chronic, and acute ketone supplements also caused significant elevation of blood ?HB levels and changed blood glucose levels.

Abstract: Methods and compositions are disclosed for delivering lutein or other antioxidant to target tissues such as the eye, in bioactive form, while protecting the antioxidant from degradation. The antioxidant is encapsulated in nanoparticles comprising a protein such as zein or a polymer such as poly(lactic-co-glycolic acid) (PLGA). Preferably a surfactant is associated with the nanoparticles as well, further helping to protect the antioxidant. After the nanoparticles are administered to the target tissue, bioactive antioxidant is released to the tissue over time. Optionally, the nanoparticles are admixed with a thermosensitive, bioadhesive gel to promote slow release of antioxidant. The methods and compositions are useful for treating or preventing conditions such as age-related macular degeneration or cataracts.

Abstract: The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

Abstract: The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.

Abstract: The present invention relates to recombinant vectors, modified microorganisms, and methods for omega-3 polyunsaturated fatty acid production.

Abstract: Methods of preventing or decreasing PEDv and/or Salmonella bacteria in animal feed, feed ingredients, and pet food are provided. The methods utilize generally safe chemical mitigants, such as medium chain fatty acids, essential oils, and sodium bisulfate. The chemical mitigants are introduced to the feed or feed ingredients at inclusion rates selected so as to prevent or decrease PEDv and/or Salmonella bacteria in the animal feed, feed ingredients, or pet food. The methods are particularly suitable for use in post-processing treatment of animal feed, feed ingredients, or pet food that will be transported and stored for multiple days or weeks.

Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating disease. The compositions of such embodiments include thiolated nitro fatty acids. The methods of various embodiments include administering an effective amount of any of these pharmaceutical compositions to a patient in need of treatment.

Abstract: The object of the present invention is to provide a composition that has preventive or ameliorative action on symptoms or diseases caused by decreased brain function. This composition contains, as its active ingredient, arachidonic acid and/or a compound having arachidonic acid as a constituent fatty acid and, particularly, an alcohol ester of arachidonic acid or a triglyceride, phospholipid or glycolipid in which all or a portion of the constituent fatty acids are arachidonic acid.

Abstract: The present invention relates generally to peroxyformic acid forming compositions, methods for forming peroxyformic acid, preferably in situ, using the peroxyformic acid forming compositions. The present invention also relates to the peroxyformic acid formed by the above compositions and methods. The present invention further relates to the uses of the peroxyformic acid, preferably in situ, for treating a surface or a target. The present invention further relates to methods for treating a biofilm using peroxyformic acid, including peroxyformic acid generated in situ.

Abstract: A series of natural soaps, both liquid and solid, and methods of making thereof, which have a synergistic effect when formulated with anti-redeposition ingredients in laundry applications both in synthetic and natural textiles and fabrics. The fatty acids and/or natural oils based series of natural soaps include both sodium and potassium soap products that interact synergistically with, preferably, known, natural anti-redeposition agents and alkaline builders creating highly effective, natural solid (bar or powdered) and liquid laundry cleaning products. Solid forms soaps are dried to an acceptable amount of moisture content for milling. Further blending is then performed with various natural anti-redeposition agents or natural products which exhibit said characteristics and/or alkaline builders. The solid forms may be formed into single dose tablets. Effervescent additives may further be included.

Abstract: The present disclosure relates to, inter alia, methods of treating cardiovascular-related disease.

Abstract: The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.

Abstract: Compositions for appetite control and/or regulation or loss of weight are described. The described compositions comprise a unique combination of ingredients, the combination including at least botanical substances, amino acids, and one or more metals, and may comprise and in some embodiments do further comprise one or more vitamins and/or caffeine. The compositions are taken by mouth and provide a multi-targeted approach for the regulation and control of appetite for subjects taking the composition. The composition is preferably taken before a meal. A recommended dose includes at least one dose of the described composition per day.

Abstract: Compositions including small molecule biochemicals, and salts and derivatives thereof, and methods for detection, treatment or prophylaxis of neuromuscular disorders are provided, including modulation of microRNA that contribute to neuromuscular disorders, including muscular dystrophies, peripheral motor neuron diseases, motor neuron diseases, neuromuscular junction diseases, myopathies, metabolic diseases of the muscle, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, motor neuron diseases, Huntington's disease, spinocerebellar ataxia, and spinal muscular atrophy.

Abstract: A compound containing one mole of a free fatty acid and one mole of the ammonium salt of the fatty acid and represented by the structural formula (I): CH3(CH2)xCOOH.CH3(CH2)xCOO?NH4+??(I) wherein x is 6, 7 or 8. Bacterial contaminated surfaces may be disinfected or bacteria removed from a bacterial contaminated surface by applying onto the surface a bactericidally effective amount of the compound.

Abstract: A compound having the formula (I) R1-COOH wherein R1 is an alkyl or alkenyl group having a C7-11 backbone, optionally branched with a C1-6 alkyl group at any C position in the backbone, or a pharmaceutically acceptable salt, amide or ester thereof, wherein the backbone of the alkyl or alkenyl group, and/or the branched alkyl groups, are optionally interrupted by one or more heteroatoms, provided that when R1 is an alkyl group having a C7 backbone, the branching does not consist only of a hexyl group at the a carbon of R1, or only of a methyl group at the ? carbon of R1, or of only single methyl groups at both the ? and ??1 carbons of R1, and provided that when R1 is an alkyl group having a C8 or C11 backbone, the branching does not consist only of a propyl group at the a carbon of R1, for use in the treatment or prevention of a disease or a biomedical condition selected from seizure-related disorders, bipolar disorders, mania, depression, migraine, attention deficit hyperactivity disorders, latent HIV infecti

Abstract: Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating diseases, including focal segmental glomerulosclerosis or pulmonary arterial hypertension. The compositions of such embodiments include activated fatty acids such as alkyl substituted fatty acids, keto fatty acids and nitro fatty acids. The methods of various embodiments include administering an effective amount of 10-nitro-9(E)-octadec-9-enoic acid to treat such diseases.

Abstract: A method of improving the appearance of periorbital dyschromia by identifying a target portion of skin in the periorbital region of a person that exhibits periorbital dyschromia and applying a personal care composition to the target portion of skin during a treatment period. The personal care composition includes an effective amount of Type I active, an effective amount of a Type II active, and a dermatologically acceptable carrier. The treatment period is of sufficient length for at least one of the actives to improve the appearance of the periorbital dyschromia.

Abstract: The present invention relates to a composition in the form of an emulsion of the oil-in-water type formed of oily globules which are each provided with a lamellar liquid crystal coating and which are dispersed in an aqueous phase, wherein it has a pH ranging from 3 to 5.5 and in that it contains at least one lipophilic surface-active agent with an HLB ranging from 2 to 5, at least one hydrophilic surface-active agent with an HLB ranging from 8 to 12 and at least one amphiphilic compound of ionic nature at a pH ranging from 3 to 5.5.

Abstract: Germicidal compositions and methods of using the same in the prevention and treatment of various hoof diseases are provided. The germicidal compositions generally comprise formic acid, at least one C2-C10 carboxylic acid, and one or more anionic surfactants, such as an ?-olefin sulfonate. The germicidal compositions may be applied topically to the hooves of an animal through various means including the use of footbaths.

Abstract: The present invention provides dietary formulations comprising polyunsaturated fatty acids and vitamin E. The present invention further provides methods of treating various conditions, generally involving administering to an individual in need thereof an effective amount of a subject dietary formulation.

Abstract: Methods of producing non-human animal models of corneal angiogenesis and corneal ectatic diseases, such as corneal keratoconus, by applying an aromatic compound to the eye of a non-human animal are described. Also described are non-human animal models of corneal angiogenesis and corneal ectatic diseases, and methods of using the non-human animal models to screen compounds that modulate corneal angiogenesis and corneal ectatic diseases.

Abstract: The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.

Abstract: Methods and compositions are disclosed for delivering lutein or other antioxidant to target tissues such as the eye, in bioactive form, while protecting the antioxidant from degradation. The antioxidant is encapsulated in nanoparticles comprising a protein such as zein or a polymer such as poly(lactic-co-glycolic acid) (PLGA). Preferably a surfactant is associated with the nanoparticles as well, further helping to protect the antioxidant. After the nanoparticles are administered to the target tissue, bioactive antioxidant is released to the tissue over time. Optionally, the nanoparticles are admixed with a thermosensitive, bioadhesive gel to promote slow release of antioxidant. The methods and compositions are useful for treating or preventing conditions such as age-related macular degeneration or cataracts.

Abstract: The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

Abstract: Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided.

Abstract: The present disclosure relates to compositions including a fatty acid soap/fatty acid mixture, and methods of use thereof. The compositions include a C5 to C12 fatty acid or mixtures thereof. The compositions show increased activity, e.g., insecticidal, soil removal, antimicrobial activity, at a controlled pH range of about 7.5 to about 9.0.

Abstract: The invention relates to matrix and layer compositions comprising a first polymer. The matrix and layer compositions are useful in the delivery of bioactives. In particular, the matrices and layers may have advantageous properties including mechanical properties and protection of bioactives and may also provide for pH-dependent release of a bioactive.

Abstract: The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.

Abstract: The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

Abstract: This invention provides a novel delivery means that enables efficient delivery of an active ingredient to a target cell. Such novel delivery means is a liposome for topical administration that consists of dioleylphosphatidylethanolamine (DOPE), phosphatidylcholine, and cationic lipid, that is not modified with PEG, and that is free of cholesterol.

Abstract: The present invention relates to a cosmetic composition based on a magnetic or magnetizable material, the preparation thereof and use thereof for surface and deep cleansing of the epidermis. Said cosmetic composition has revealed to be particularly useful for preparing a mask for cleansing the epidermis of the face, breast, hands and body and, simultaneously, for maintaining the aesthetic appearance and functional efficiency thereof.

Abstract: The present invention provides a formulation comprising: i) a lipid matrix; ii) at least one thiolated antioxidant; iii) optionally at least one bioactive agent; and iv) optionally at least one chelating agent.

Abstract: The invention relates to the use of specifically designed lipid component with optimal fatty acid profile, an enhanced portion of the palmitic acid residues in the sn-2 position and present as lipid globules with a phospholipid coating for an early in life diet for improving the development of a healthy body composition, in particular prevention of obesity, later in life.

Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.

Abstract: Provided herein are exemplary compositions, products, and capsules utilizing POA, EPA, blends of POA and EPA, total algal oil compositions, and/or whole biomass compositions in methods of inhibiting inflammation including in cardiovascular disease, diabetes, obesity, stroke, metabolic syndromes, dementia, Alzheimer's disease, and/or cancer. The exemplary compositions, products, and capsules may be orally, topically, intravenously, and/or subcutaneously administered. The exemplary compositions herein may be used as feed, food, food supplements, beverages, beverage supplements, nutritional products, products for athletic performance, pharmaceutical products, and/or medical products for mammalian use, including humans.

Abstract: Disclosed herein are methods of inactivating and/or decolonizing bacteria on a surface. The present invention also discloses methods for treatment of epithelial conditions caused or aggravated by bacteria, such as acne vulgaris, in a subject in need thereof. The present invention additionally discloses inventive compounds and compositions that exhibit anti-bacterial and/or anti-inflammatory effects.

Abstract: Provided are compositions for attracting and/or stimulating oviposition. The compositions comprise a suitable carrier and a bacterium capable of producing nonanoic acid, tetradecanoic acid, or methyl tetradecanoate; Bacillus thuringiensis; Lactococcus lactis; Klebsiella oxytoca; Shigella dysenteriae; Brevundimonas vesicularis; a supernatant of a culture of any of the these bacteria; nonanoic acid; tetradecanoic acid; or methyl tetradecanoate, or any combination thereof, at a concentration effective to attract the mosquito to a target. The compositions may be comprised within a kit or trap. Also provided are methods of attracting mosquitoes to a target.

Abstract: An object of the present invention is to provide a drug that contains a compound for inhibiting neutral lipid accumulation in cardiovascular tissue or cells and has an excellent prophylactic or therapeutic effect on cardiovascular complications of diabetes. The present invention relates to a prophylactic and/or therapeutic agent for cardiovascular complications of diabetes, the agent containing a compound (preferably a medium-chain fatty acid and/or a medium-chain triglyceride) for inhibiting neutral lipid accumulation.

Abstract: Microbial growth inhibiting solutions and methods of employing the microbial growth inhibiting solutions in flushing and coating medical devices are disclosed. In alternative embodiments, the microbial growth inhibiting solutions include combinations of a chelating agent with a C4-C9 carboxylate antimicrobial agent, for example, such as n-octanoic acid. Methods of using these microbial growth inhibiting solutions for coating a medical device and for inhibiting catheter infection are also disclosed.

Abstract: A composition for treating, ameliorating and/or preventing conditions associated with cognitive decline and/or motor neuron death comprise a fatty acid component enriched for one or more activated fatty acids and a nutraceutically acceptable excipient. A method for treating, ameliorating and/or preventing conditions associated with cognitive decline and/or motor neuron death includes administering a fatty acid component enriched for one or more activated fatty acids.

Abstract: Described herein are nitrated lipids and methods of making and using the nitrated lipids.

Abstract: Compositions and methods for modulating melanogenesis by modifying tyrosinase palmitoylation are provided.